Distribution · GCC · Announced 17 Oct 2026
Macleods Pharmaceuticals → New Country Healthcare
Distribution deal between Macleods Pharmaceuticals (India) and New Country Healthcare (United Arab Emirates), announced 17 Oct 2026.
Parties: Macleods Pharmaceuticals Limited (India) → New Country Healthcare LLC (NCH) (United Arab Emirates)
- Deal type
- Distribution
- Value
- Not stated
- Territory
- UAE (marketing & distribution); NCH's established Gulf footprint provides expansion runway
- Therapeutic area
- CNS / Neurology
- Asset
- Macleods pharmaceutical portfolio — initial focus on CNS (central nervous system) products, with stated expansion to additional therapeutic areas
- Announced
- 17 Oct 2026
Our analysis
Why this matters
This is a pairing of two operators at the top of their respective games, not a speculative tie-up. Macleods closed FY2024-25 (March 2025) with ₹9,308 crore (~US$1.1 billion) in consolidated revenue and a 24.5% net profit margin (₹2,276 crore net profit) — one of India's most profitable large generics makers, ranked roughly 9th nationally, selling into 170+ countries from 14 formulation plants and 2 API facilities. NCH, founded in Dubai in 1978 as Country Pharmacy and rebranded in 1990, has spent 48 years building arguably the UAE's most entrenched independent distribution franchise: 1,500+ SKUs, MOHAP-licensed, ISO 9001:2015 and HACCP certified, with warehouses in Warsan (Dubai) and Mussafah (Abu Dhabi), and a track record of representing Chiesi, Recordati, Jamp Pharma and Vitabiotics. When a US$1.1bn manufacturer with Macleods' economics chooses a regional distributor, it is buying regulatory velocity and shelf access — and NCH is paying for that choice with the credibility of its multinational roster.
The full analysis is free to read with a work email on this page.
Source: New Country Healthcare